Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)

Trial Profile

A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs Tilsotolimod (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILLUMINATE-101
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2018 According to an Idera Pharmaceuticals media release, translational data from the study continues to be collected, analyzed and is planned to be submitted for presentation at a medical oncology conference in 2019.
    • 06 Nov 2018 According to an Idera Pharmaceuticals media release, enrollment has been completed in all four dose ranging cohorts; 41 patients enrolled. Enrollment will be continued into the refractory melanoma cohort at the 8 mg dose of intratumoral tilsotolimod as monotherapy.
    • 05 Jun 2018 Results of pooled data from two phase1 trials (NCT03052205 and NCT02644967), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top